Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$7.09 - $89.45 $6.45 Million - $81.4 Million
-909,722 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$80.85 - $128.49 $4.02 Million - $6.39 Million
-49,701 Reduced 5.18%
909,722 $77.1 Million
Q3 2021

Nov 15, 2021

SELL
$81.97 - $106.94 $356,733 - $465,402
-4,352 Reduced 0.45%
959,423 $92.1 Million
Q2 2021

Aug 16, 2021

SELL
$77.2 - $126.54 $1.26 Million - $2.06 Million
-16,263 Reduced 1.66%
963,775 $89.6 Million
Q1 2021

May 17, 2021

BUY
$110.45 - $164.47 $854,551 - $1.27 Million
7,737 Added 0.8%
980,038 $111 Million
Q4 2020

Feb 16, 2021

SELL
$60.78 - $154.03 $16.3 Million - $41.4 Million
-268,672 Reduced 21.65%
972,301 $143 Million
Q3 2020

Nov 16, 2020

SELL
$45.05 - $59.27 $1.15 Million - $1.52 Million
-25,567 Reduced 2.02%
1,240,973 $73.5 Million
Q2 2020

Aug 14, 2020

BUY
$42.74 - $66.25 $665,889 - $1.03 Million
15,580 Added 1.25%
1,266,540 $68.5 Million
Q1 2020

May 15, 2020

SELL
$38.18 - $73.95 $9.56 Million - $18.5 Million
-250,421 Reduced 16.68%
1,250,960 $59.7 Million
Q4 2019

Feb 14, 2020

SELL
$13.9 - $76.65 $2.35 Million - $13 Million
-169,220 Reduced 10.13%
1,501,381 $108 Million
Q3 2019

Nov 14, 2019

SELL
$10.24 - $17.57 $2.45 Million - $4.2 Million
-238,785 Reduced 12.51%
1,670,601 $24 Million
Q2 2019

Aug 14, 2019

BUY
$6.2 - $12.0 $2.89 Million - $5.59 Million
466,050 Added 32.29%
1,909,386 $22.3 Million
Q1 2019

May 15, 2019

BUY
$6.43 - $9.44 $857,286 - $1.26 Million
133,326 Added 10.18%
1,443,336 $9.43 Million
Q4 2018

Feb 14, 2019

BUY
$6.11 - $10.43 $8 Million - $13.7 Million
1,310,010 New
1,310,010 $9.3 Million

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $450M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Arrow Mark Colorado Holdings LLC Portfolio

Follow Arrow Mark Colorado Holdings LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

News

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.